SG11202101069SA - Microrna-based therapy targeted against lcp-1 positive cancers - Google Patents

Microrna-based therapy targeted against lcp-1 positive cancers

Info

Publication number
SG11202101069SA
SG11202101069SA SG11202101069SA SG11202101069SA SG11202101069SA SG 11202101069S A SG11202101069S A SG 11202101069SA SG 11202101069S A SG11202101069S A SG 11202101069SA SG 11202101069S A SG11202101069S A SG 11202101069SA SG 11202101069S A SG11202101069S A SG 11202101069SA
Authority
SG
Singapore
Prior art keywords
microrna
lcp
based therapy
targeted against
positive cancers
Prior art date
Application number
SG11202101069SA
Other languages
English (en)
Inventor
Marianna Prokopi
Original Assignee
Theramir Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theramir Ltd filed Critical Theramir Ltd
Publication of SG11202101069SA publication Critical patent/SG11202101069SA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/7105Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90Stable introduction of foreign DNA into chromosome
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/14Type of nucleic acid interfering N.A.
    • C12N2310/141MicroRNAs, miRNAs
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SG11202101069SA 2018-08-08 2019-08-08 Microrna-based therapy targeted against lcp-1 positive cancers SG11202101069SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18020374 2018-08-08
PCT/EP2019/071341 WO2020030750A1 (fr) 2018-08-08 2019-08-08 Thérapie à base de microarn ciblant des cancers positifs à lcp-1

Publications (1)

Publication Number Publication Date
SG11202101069SA true SG11202101069SA (en) 2021-03-30

Family

ID=63207480

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202101069SA SG11202101069SA (en) 2018-08-08 2019-08-08 Microrna-based therapy targeted against lcp-1 positive cancers

Country Status (13)

Country Link
EP (2) EP3833760B1 (fr)
JP (2) JP7545970B2 (fr)
KR (1) KR20210044247A (fr)
CN (1) CN112567034A (fr)
AU (1) AU2019319623A1 (fr)
BR (1) BR112021002321B1 (fr)
CA (1) CA3108172A1 (fr)
EA (1) EA202190474A1 (fr)
IL (1) IL280622A (fr)
MX (1) MX2021001517A (fr)
PL (1) PL3833760T3 (fr)
SG (1) SG11202101069SA (fr)
WO (1) WO2020030750A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111643527B (zh) * 2020-07-22 2020-12-29 广东赛尔生物科技有限公司 转基因干细胞外泌体在制备药物或美白化妆品中的用途
CN112294960B (zh) * 2020-10-30 2022-02-08 浙江大学 微小分子RNA-30b-5p作为靶分子的用途
WO2022154601A1 (fr) * 2021-01-14 2022-07-21 연세대학교 산학협력단 Nouveaux biomarqueurs du cancer du pancréas et leurs utilisations
CN114350800B (zh) * 2021-12-29 2024-03-19 中南大学湘雅医院 Sphk1在制备pd-l1/pd-1单抗肿瘤免疫治疗药物中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013048734A1 (fr) * 2011-09-28 2013-04-04 Tufts Medical Center, Inc. Traitement et prévention des maladies cardiovasculaires à l'aide de vésicules, microvésicules et exosomes lipidiques d'origine cellulaire
RS63237B1 (sr) * 2012-11-26 2022-06-30 Modernatx Inc Terminalno modifikovana rnk
AU2014217615B2 (en) * 2013-02-12 2018-11-15 Reneuron Limited Method of producing microparticles
WO2016166600A1 (fr) 2015-04-15 2016-10-20 Trojantec Technologies Ltd Administration de micro-arn à l'aide de microparticules de cellules souches mésenchymateuses
WO2017005773A1 (fr) * 2015-07-07 2017-01-12 Universite de Bordeaux Utilisation de micro-arn ciblant la bêta-caténine pour le traitement du cancer du foie
US20180127786A1 (en) * 2016-09-23 2018-05-10 Casebia Therapeutics Limited Liability Partnership Compositions and methods for gene editing

Also Published As

Publication number Publication date
CN112567034A (zh) 2021-03-26
US20210369760A1 (en) 2021-12-02
EP3833760B1 (fr) 2024-07-17
BR112021002321B1 (pt) 2023-11-28
CA3108172A1 (fr) 2020-02-13
PL3833760T3 (pl) 2024-10-21
JP2024095750A (ja) 2024-07-10
JP7545970B2 (ja) 2024-09-05
MX2021001517A (es) 2021-04-19
EP4424380A2 (fr) 2024-09-04
EP3833760C0 (fr) 2024-07-17
EA202190474A1 (ru) 2021-04-15
KR20210044247A (ko) 2021-04-22
WO2020030750A1 (fr) 2020-02-13
BR112021002321A2 (pt) 2021-05-11
AU2019319623A1 (en) 2021-02-25
IL280622A (en) 2021-03-25
JP2021533822A (ja) 2021-12-09
EP3833760A1 (fr) 2021-06-16

Similar Documents

Publication Publication Date Title
IL271946A (en) Combination for cancer treatment
IL259017A (en) Cancer cure is intended
IL277336A (en) combined treatment
GB201707153D0 (en) Therapy
GB201804255D0 (en) Macrophage-based therapy
ZA202005847B (en) Cancer therapy
IL280622A (en) A microRNA-based therapy targeting lcp-1-positive cancer
GB201719646D0 (en) Therapy
GB201708663D0 (en) Therapy
ZA201904736B (en) Targeted doxorubicin-gold nanoconjugates for tumor therapy
GB201819853D0 (en) Therapy
IL280968A (en) Combined treatment
IL279908A (en) Combined treatment
GB201704909D0 (en) Cancer therapy
IL280729A (en) Combined treatment
GB201817385D0 (en) Therapy
GB201711855D0 (en) Cancer therapy
GB201806463D0 (en) Cancer therapy
GB201820895D0 (en) Therapy
GB201814038D0 (en) Ilven therapy
GB201711250D0 (en) Cancer therapy
GB201710198D0 (en) Cancer therapy
GB201815579D0 (en) Combination therapy
GB201814207D0 (en) Combination Therapy
GB201706046D0 (en) Cancer therapy